Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies

Summary

This is a two-part study in subjects with hematologic malignancies designed to find the maximum tolerated dose (MTD) of GSK690693 (Part 1). Part 2 is designed to determine the efficacy of GSK690693 in a subset of subjects with hematologic malignancies.

Timeline

Start

2008-04

Primary completion

2009-12

Completion

2009-12

Outcome

Outcome not reported

Stopped (Enrollment): “Study Cancelled before enrollment”

Drugs

Indications